@article{Philipp Schommers_Daniel Gillor_Marcus Hentrich_Christoph Wyen_Timo Wolf_Mark Oette_Alexander Zoufaly_Jan-Christian Wasmuth_Johannes R. Bogner_Markus Müller_Stefan Esser_Alisa Schleicher_Björn Jensen_Albrecht Stoehr_Georg Behrens_Alexander Schultze_Jan Siehl_Jan Thoden_Ninon Taylor_Christian Hoffmann_2018, place={Pavia, Italy}, title={Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study}, volume={103}, url={https://haematologica.org/article/view/8456}, DOI={10.3324/haematol.2017.180893}, abstractNote={Outcome of HIV-infected patients with AIDS-related lymphomas has improved during recent years. However, data on incidence, risk factors, and outcome of relapses in AIDS-related lymphomas after achieving complete remission are still limited. This prospective observational multicenter study includes HIV-infected patients with biopsy- or cytology-proven malignant lymphomas since 2005. Data on HIV infection and lymphoma characteristics, treatment and outcome were recorded. For this analysis, AIDS-related lymphomas patients in complete remission were analyzed in terms of their relapse- free survival and potential risk factors for relapses. In total, 254 of 399 (63.7%) patients with AIDS-related lymphomas reached a complete remission with their first-line chemotherapy. After a median follow up of 4.6 years, 5-year overall survival of the 254 patients was 87.8% (Standard Error 3.1%). Twenty-nine patients relapsed (11.4%). Several factors were independently associated with a higher relapse rate, including an unclassifiable histology, a stage III or IV according to the Ann Arbor Staging System, no concomitant combined antiretroviral therapy during chemotherapy and R-CHOP-based compared to more intensive chemotherapy regimens in Burkitt lymphomas. In conclusion, complete remission and relapse rates observed in our study are similar to those reported in HIV-negative non-Hodgkin lymphomas. These data provide further evidence for the use of concomitant combined antiretroviral therapy during chemotherapy and a benefit from more intensive chemotherapy regimens in Burkitt lymphomas. Modifications to the chemotherapy regimen appear to have only a limited impact on relapse rate.}, number={5}, journal={Haematologica}, author={Philipp Schommers and Daniel Gillor and Marcus Hentrich and Christoph Wyen and Timo Wolf and Mark Oette and Alexander Zoufaly and Jan-Christian Wasmuth and Johannes R. Bogner and Markus Müller and Stefan Esser and Alisa Schleicher and Björn Jensen and Albrecht Stoehr and Georg Behrens and Alexander Schultze and Jan Siehl and Jan Thoden and Ninon Taylor and Christian Hoffmann}, year={2018}, month={Apr.}, pages={857-864} }